Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:CRSP News 22 June 2025 - 24 January 2026

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics shares slipped 0.5% to $60.51 in premarket trading Friday after CEO Samarth Kulkarni sold 90,000 shares for about $5.2 million under a preset plan, an SEC filing showed. The stock had surged 11.1% Thursday on heavy volume. Options trading spiked, with focus on April $90 calls. Bank of America trimmed its price target to $89 but kept a Buy rating.
23 January 2026
··
CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next

CRISPR Therapeutics shares fell 4.5% to $53.84 Friday ahead of its Monday presentation at the J.P. Morgan Healthcare Conference. Investors are focused on updates for Casgevy’s commercial rollout, patient starts, and payer coverage. The therapy, approved for sickle cell disease, is co-developed with Vertex, which records product revenue. Traders await signals on 2026 projections and revenue ramp-up.
12 January 2026
··
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

NEW YORK, Dec. 27, 2025, 4:58 p.m. ET — Market closed (U.S. equities are shut for the weekend) CRISPR Therapeutics AG (NASDAQ: CRSP) heads into the final trading stretch of 2025 with investors balancing two forces that often define biotech stocks: headline-driven momentum and long-duration fundamental risk. The stock finished the most recent regular session (Friday, Dec. 26) at $55.08, down 2.87%, after trading between $56.54 and $53.76. In after-hours trading, CRSP was last shown around $55.24 late Friday evening. StockAnalysis That Friday move came against a holiday-thinned tape on Wall Street. Reuters described the broader market session as light-volume
27 December 2025
··
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

Updated: December 4, 2025 Key takeaways CRISPR Therapeutics stock today: price, volatility and positioning As of pre‑market trading on December 4, 2025, CRISPR Therapeutics AG (NASDAQ: CRSP) is changing hands at roughly $56, just above Wednesday’s close of $55.99, after jumping 8.5% in the last regular session. stockinvest.us+1 Over the past 12 months, CRSP has traded between about $30.04 and $78.48, leaving today’s price squarely in the middle of its 52‑week range. stockinvest.us A few quick stats: Technically, services like StockInvest.us classify CRSP as a “hold/accumulate” with a wide expected three‑month range (~$43–$64), while Intellectia’s model calls it a “Strong
4 December 2025
·
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Current News Stock Price and Market Activity CRSP is trading around the mid-$60s ahead of Monday’s open. By Reuters (Nov 2) it was ~$64.04 (up +4.86% on the day) Reuters. (Nasdaq closes on Oct 31 showed ~$63.99 Reuters.) Over the past month CRSP has gained roughly 17% Genengnews, boosted by recent data releases. For example, a 3-day rally in mid-Oct lifted CRSP ~5% after the SyNTase/CTX460 results were announced Genengnews. Technical indicators are mixed: the 14-day RSI is ~50 (neutral) and the MACD is slightly negative Investing. Shorter moving averages (5/10/20-day around $63–$63.8) are giving buy signals Investing, but the
2 November 2025
······
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at the ESGCT conference – showed that a single dose of CTX460 delivered by lipid nanoparticles corrected the disease-causing mutation in >90% of liver cells and boosted functional AAT protein ~5-fold in animal models globenewswire.com. “The preclinical results demonstrate the potential of CTX460, developed using our novel SyNTase editing platform, to correct the mutation with precision and efficiency,” said CRISPR CMO
19 October 2025
···
June 2025 Science Breakthroughs and Projects: Medicine, Space, Climate, AI & More

June 2025 Science Breakthroughs and Projects: Medicine, Space, Climate, AI & More

In a Nature study, cancer cells were shown to siphon mitochondria from nearby nerve cells via microscopic tubes, a mechanism called mitochondrial hijacking that promotes metastasis. A separate Science News report described tumor DNA detectable in blood years before diagnosis, boosting early cancer screening prospects. An in vivo “exercise in a pill” approach in mice used a molecule that mimics workout benefits, improving metabolic health. Casgevy, the CRISPR-based sickle-cell gene therapy approved in late 2024, has begun treatment in over 90 patients globally. CRISPR Therapeutics’ CTX310, an in vivo ANGPTL3-targeting CRISPR therapy, produced dose-dependent triglyceride reductions up to 82% and
28 June 2025
···
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Pfizer Inc., in collaboration with BioNTech, co-developed the first FDA-approved mRNA COVID-19 vaccine, Comirnaty. Roche Holding AG is the world’s largest biotech company and a leader in oncology treatments (Herceptin) and diagnostics. Moderna, Inc. pioneered mRNA vaccine technology and its COVID-19 vaccine was among the first mRNA medicines approved, while expanding mRNA therapeutics for cancer and rare diseases. Illumina, Inc. is a market leader in DNA sequencing with platforms such as NovaSeq that enabled the concept of a $1,000 genome. CRISPR Therapeutics AG is a leading CRISPR-Cas9 gene editing company developing exa-cel for sickle cell disease and other therapies. Ginkgo
22 June 2025
···········

Stock Market Today

Morgan Stanley stock price bounces after three-day slide; what to watch before Monday

Morgan Stanley stock price bounces after three-day slide; what to watch before Monday

7 February 2026
Morgan Stanley shares rose 2.34% to $179.96 Friday, snapping a three-day slide as the Dow closed above 50,000 for the first time. About 9.1 million MS shares traded hands. The rebound followed Thursday’s 2.35% drop and came amid renewed rate-cut speculation and surging AI spending. Morgan Stanley remains 6.6% below its January high.
Lam Research stock price jumps 8% as chip rally returns — what to watch next week

Lam Research stock price jumps 8% as chip rally returns — what to watch next week

7 February 2026
Lam Research shares surged 8.3% to $231.01 Friday, with after-hours trading flat. The move followed a broad rally in chip stocks, pushing the PHLX semiconductor index up 5.7% as Nvidia, AMD, and Broadcom advanced. Lam announced a $0.26 quarterly dividend and a senior executive exercised 53,925 shares. Investors await U.S. jobs and inflation data next week.
Goldman Sachs stock jumps on Anthropic AI push — what to watch before Monday

Goldman Sachs stock jumps on Anthropic AI push — what to watch before Monday

7 February 2026
Goldman Sachs shares jumped 4.3% to $928.75 Friday after confirming it is working with AI startup Anthropic on internal “AI agents.” The stock’s rally helped lift the Dow above 50,000 for the first time. Delayed U.S. jobs and inflation data are due midweek and could affect rate expectations. Goldman also filed for new structured notes tied to the Russell 2000 and S&P 500.
Go toTop